Protection of biomanufacturing processes from virus contamination through upstream virus filtration of cell culture media.
ATMP
biopharmaceuticals
media
nanofiltration
virus filtration
virus safety
Journal
Biotechnology and bioengineering
ISSN: 1097-0290
Titre abrégé: Biotechnol Bioeng
Pays: United States
ID NLM: 7502021
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
23
05
2023
received:
03
04
2023
accepted:
07
06
2023
medline:
15
9
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Cell-based manufacturing processes have occasionally been exposed to adventitious viruses, leading to manufacturing interruptions and unstable supply situations. The rapid progress of advanced therapy medicinal products needs innovative approaches to avoid any unwelcome reminder of the universal presence of viruses. Here, we investigated upstream virus filtration as a clearance step for any product too complex for downstream interventions. Culture media virus filtration was investigated with respect to virus clearance capacities under extreme conditions such as high process feed loading (up to ~19,000 L/m²), long duration (up to 34 days), and multiple process interruptions (up to 21 h). The small nonenveloped Minute virus of mice was used as relevant target virus, and as worse-case challenge for the investigated virus filters with a stipulated pore-size of about 20 nm. Certain filters-especially of the newer second generation-were capable of effective virus clearance despite the harsh regimen they were subjected to. The biochemical parameters for un-spiked control runs showed the filters to have no measurable impact on the composition of the culture media. Based on these findings, this technology seems to be quite feasible for large volume premanufacturing process culture media preparations.
Substances chimiques
Culture Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2917-2924Informations de copyright
© 2023 Takeda Manufacturing Austria AG. Biotechnology and Bioengineering published by Wiley Periodicals LLC.
Références
Asahi KASEI. (2018a). TAE34036, validation report planova bioex filters.
Asahi KASEI. (2018b). TAE33015, planova virus removal filters product specification sheet.
Barone, P. W., Wiebe, M. E., Leung, J. C., Hussein, I. T. M., Keumurian, F. J., Bouressa, J., Brussel, A., Chen, D., Chong, M., Dehghani, H., Gerentes, L., Gilbert, J., Gold, D., Kiss, R., Kreil, T. R., Labatut, R., Li, Y., Müllberg, J., Mallet, L., … Springs, S. L. (2020). Viral contamination in biologic manufacture and implications for emerging therapies. Nature Biotechnology, 38(5), 563-572. https://doi.org/10.1038/s41587-020-0507-2
Berting, A., Farcet, M. R., & Kreil, T. R. (2010). Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing. Biotechnology and Bioengineering, 106(4), 598-607. https://doi.org/10.1002/bit.22723
Bethencourt, V. (2009). Virus stalls Genzyme plant. Nature Biotechnology, 27, 681. https://doi.org/10.1038/nbt0809-681a
Cao, X., Stimpfl, G., Wen, Z., Frank, G., & Hunter, G. (2013). Identification and root cause analysis of cell culture media precipitates in the viral deactivation treatment with high-temperature/short-time method. PDA Journal of Pharmaceutical Science and Technology, 67(1), 63-73. https://doi.org/10.5731/pdajpst.2013.00894
EMEA/CPMP/BWP/268/95. (1996). The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit: CPMP Biotechnology Working Party-Note for guidance on virus validation studies: The design, contribution, and interpretation of studies validating the inactivation and removal of viruses.
FDA Center for Biologics Evaluation and Research. (1997). Points to consider in the manufacture and testing of monoclonal antibody products for human use.
Garnick, R. L. (1998). Raw materials as a source of contamination in large-scale cell culture. Developments in Biological Standardization, 93, 21-29.
Gombold, J., Karakasidis, S., Niksa, P., Podczasy, J., Neumann, K., Richardson, J., Sane, N., Johnson-Leva, R., Randolph, V., Sadoff, J., Minor, P., Schmidt, A., Duncan, P., & Sheets, R. L. (2014). Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products. Vaccine, 32(24), 2916-2926. https://doi.org/10.1016/j.vaccine.2014.02.021
Grillberger, L., Kreil, T. R., Nasr, S., & Reiter, M. (2009). Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnology Journal, 4(2), 186-201. https://doi.org/10.1002/biot.200800241
ICH-Q5A(R2). (2023). Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
Johnson, S. A., Chen, S., Bolton, G., Chen, Q., Lute, S., Fisher, J., & Brorson, K. (2022). Virus filtration: A review of current and future practices in bioprocessing. Biotechnology and Bioengineering, 119(3), 743-761. https://doi.org/10.1002/bit.28017
Kreil, T. R. (2018). Building blocks of the viral safety margins of industrial plasma products. Annals of Blood, 3, 14. https://doi.org/10.21037/aob.2018.02.01
Leisi, R., Widmer, E., Gooch, B., Roth, N. J., Ros, C. (2021). Mechanistic insights into flow-dependent virus retention in different nanofilter membranes. Journal of Membrane Science, 636, 119548. https://doi.org/10.1016/j.memsci.2021.119548
Merck Millipore. (2012). DS1077EN00, Data sheet viresolve NFP filter.
Merck Millipore. (2021). DS1401EN00, data sheet Viresolve Barrier Filters.
Meunier, S. M., Todorovic, B., Dare, E. V., Begum, A., Guillemette, S., Wenger, A., Saxena, P., Campbell, J. L., Sasges, M., & Aucoin, M. G. (2016). Impact of dissolved oxygen during UV-irradiation on the chemical composition and function of CHO cell culture media. PLoS ONE, 11(3), e0150957. https://doi.org/10.1371/journal.pone.0150957
Moody, M., Alves, W., Varghese, J., & Khan, F. (2011). Mouse minute virus (MMV) contamination-A case study: Detection, root cause determination, and corrective actions. PDA Journal of Pharmaceutical Science and Technology, 65(6), 580-588. https://doi.org/10.5731/pdajpst.2011.00824
Nims, R. W. (2006). Detection of adventitious viruses in biologicals-A rare occurrence. Developments in Biologicals, 123, 153-164.
Opeyemi, O. A., Johnson, S. A., Faison, T., Azer, N., Cullinan, J. L., Dement-Brown, J., & Lute, S. C. (2022). An updated analysis of viral clearance unit operations for biotechnology manufacturing. Current Research in Biotechnology, 4, 190-202. https://doi.org/10.1016/j.crbiot.2022.03.002
Pall Life Sciences. (2010). GN08.2593 USD2485, Pall Minidisc Virus removal Filter Capsules.
Pall Life Sciences. (2012). GN10.4151 USD2770, Pall Minidisc Capsules with Pegasus SV4 Virus Removal Filter Membrane.
Pall Life Sciences. (2016). GN16.6503 USD3141, Pall Microdisc Capsules with Pegasus Prime Virus Removal Filter Membrane.
Parker, E. T., & Lollar, P. (2021). Conformation of the von Willebrand factor/factor VIII complex in quasi-static flow. Journal of Biological Chemistry, 296, 100420. https://doi.org/10.1016/j.jbc.2021.100420
PDA. (2022). Virus filtration. Technical report No. 41. PDA J Pharm Sci Technol.
Sartorius Stedim Biotech GmbH. (2011). SPK2065-e11029, Virosart CPV MaxiCaps and Cartridges.
Sartorius Stedim Biotech GmbH. (2014). SPK2143-e141201, Virosart HF Lab Modules.
Wieser, A., Berting, A., Medek, C., Poelsler, G., & Kreil, T. R. (2015). The evolution of down-scale virus filtration equipment for virus clearance studies. Biotechnology and Bioengineering, 112(3), 633-637. https://doi.org/10.1002/bit.25452
Wieser, A., Berting, A., Medek, C., Poelsler, G., & Kreil, T. R. (2016). Virus filtration and flow variation: An approach to evaluate any potential impact on virus retention. PDA Journal of Pharmaceutical Science and Technology, 70(4), 325-331. https://doi.org/10.5731/pdajpst.2015.006346